Oncimmune Taps Former Luminex, Abbott Exec To Head Asia Sales
Executive Summary
Early lung cancer detection company Oncimmune gears up to target Asian markets with the appointment of Maarten Brusse as chief commercial officer for the region.
You may also be interested in...
Oncimmune Hits IPO Target
Early cancer detection specialist Oncimmune has joined AIM, the London Stock Exchange’s international market for emerging companies, after successfully completing its initial public offering and raising £11m ($15.7m) in gross proceeds. The company’s market capitalization on admission to AIM is around £66.3m; it is trading under the symbol “ONC.L”.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.